echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Inventory: A selection of Lancet studies on September 12, 2020.

    Inventory: A selection of Lancet studies on September 12, 2020.

    • Last Update: 2020-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    DoI: https://doi.org/10.1016/S0140-6736 (20)20) to prevent mother-to-child transmission of the cytocytovirus in early pregnancy 31868-7 cytocytovirus infection is a common congenital infection, primary maternal infection, the incidence of offspring is higher, recently researchers looked at the effect of pyrethrovir to prevent cytocytovir to prevent the primary infection of the mother in the early stages of pregnancy vertical transmission to the fetus.
    90 patients were involved in the study, including 45 patients in the psilocybe group (all single births), 45 patients in the placebo group (43 listed fetuses and 2 pairs of twins), and patients aged 18 or over who were pregnant Primary cytokine viral infection diagnosed before or three months of pregnancy, random oral pyrethroid (8 grams per day, twice a day) or placebo, follow-up to amniotic membrane puncture after 21-22 weeks of pregnancy.
    end of this study is the vertical propagation rate of cytocytovirus.
    In the psilocybe group, 5 (11%) of patients tested positive for fetal cytomevirus after amniotic membrane puncture, while 47 cases in the placebo group and 14 (30%) fetal positive after amniotic membrane puncture (the ratio of vertical transmission of cytomeral virus was 0.29).
    patients with primary cytokine virus infection in the early stages of pregnancy, 2 cases of cytokine amniotic membrane puncture in the pyrethroid group tested positive, significantly lower than the 11 cases in the placebo group (11% vs 48%).
    adverse events that had no clinical significance between the two groups.
    :2: Methadone combined with misoprostol treatment for abortion DOI: https://doi.org/10.1016/S0140-6736 (20) 31788-8 The anti-progesterone drug methadone and prostatin-like mesoprostol are common drugs used to treat abortion, and researchers recently examined the therapeutic effect of methadone combined with misoprostol on abortion.
    MifeMiso study was conducted in 28 hospitals across the UK.
    16 years of age and older, after pelvic ultrasound was diagnosed as a single dose of oral 200 mg of non-estone or placebo, two days later, vaginal, oral or under the tongue containing 800 mg of misoprostol.
    result of the study was the failure rate of miscarriage within 7 days, defined as the unnatural discharge of the pregnancy sac.
    711 women participated in the study, including 357 in the methadone-misoprostol group, 354 in the placebo-misoprostol group, and 98 percent of the participants completed the study. Of the 348 participants in the
    -methadone-misoprostol group, 59 (17%) did not naturally discharge the pregnancy sacs within 7 days, while 82 (24%) of the 348 participants in the placebo-misoprostol group did not naturally discharge the sacs (risk ratio. Sixty-two (17%) of the 355 participants in the
    -methadone plus-misoprostol group needed surgical intervention to complete the abortion, while 87 (25%) of the 353 participants in the placebo-misoprostol group needed surgical treatment (0.71).
    rate of adverse events did not differ between the two groups.
    3: Mavacamten, a cardiomyosin inhibitor, treats obstructive hypertrophy cardiomyopathy DOI: https://doi.org/10.1016/S0140-6736 (20)31792-X myocardial overstrection is an important pathological feature of hypertrophy cardiomyopathy (LVOT) blocking.
    currently has fewer drugs available for hypertrophomyopathy, poor tolerance, and lack of disease specificity.
    recently evaluated the efficacy and safety of myomyosin inhibitor mavacamten for symptomatic obstructive hypertrophobic cardiomyopathy.
    the EXPLORER-HCM study was conducted in 68 cardiovascular centers in 13 countries, with LVOT pressure differences of 50 mmHg and NYHA II-III patients divided into mavacamten (starting dose 5 mg) or placebo groups for 30 weeks of continuous treatment.
    end point is an increase in peak oxygen consumption (pVO2) of 1.5 mL/kg per minute, with a reduction of the NYHA grade at least once, or an increase of 3.0 mL/kg in pVO2 and no deterioration of the NYHA rating.
    end points were changes in post-sport LVOT gradient, pVO2, NYHA rating, KCCQ-CSS score, and HCMSQ-SoB score.
    251 patients were randomly assigned to the mavacamten group (123) and the placebo group (128).
    45 patients (37%) in the Mavacamten group and 22 (17%) in the placebo group met the main endpoint (difference of 19.4%).
    compared to the placebo group, the LVOT gradient decreased significantly after exercise in the mavacamten group (-36 mm Hg), pVO2 increased more (-1.4 mL/kg per min), and the symptom score increased even more (KCCQ-CSS s9.1; HCMSQ-SoB -1.8).
    NYHA in 80 patients in the Mavacamten group was raised by at least one level, while in the placebo group there were only 40.
    are similar in security and tolerance to both groups.
    reactions that require urgent treatment are generally mild.
    a patient in the placebo group died suddenly.
    source: MedSci Originals !-- content presentation ends -- !-- to determine whether the login ends.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.